A new pharmaceutical manufacturing facility is set to commence operations in Nadi, Fiji, within the coming months, which is expected to alleviate the persistent shortages of essential medicines in the country. Parvish Kumar, the founder and CEO of Pacific Specialist Healthcare (PSH) Hospitals, made the announcement during a signing ceremony for a long-term lease agreement with Sun Insurance Co Ltd. This new facility will be located in SUN Centre 2, which is currently under construction adjacent to the existing SUN Centre 1.
Kumar emphasized that the establishment of the drug plant demonstrates PSH’s commitment to long-term investment in Fiji’s healthcare system, aiming to secure advanced medical services for decades to come. Apart from the pharmaceutical plant, which will occupy the first two levels of the building, the upper floors will feature an advanced Pacific Cardiac unit. This unit will not only support existing open-heart surgeries but also plans to introduce organ transplant services in the near future.
The initiative aligns with the government’s National Development Plan, specifically targeting the growth of medical tourism in Fiji. Kumar indicated that the expansion of hospital capacities and technological advancements are strategic moves to enhance Fiji’s position as a medical tourism hub.
He expressed optimism that within seven to eight months of the operational launch of the plant, Fiji will no longer experience medicinal drug shortages. As Kumar stated, “Nadi will actually become a medical hub of Fiji and the Pacific,” reflecting a hopeful vision for increased accessibility to healthcare services for both locals and visitors.
This development represents a significant step towards improving healthcare infrastructure in Fiji and highlights the potential for increased investment in the healthcare sector. With the ongoing advancements, patients are expected to benefit greatly from reduced reliance on imported pharmaceuticals and the introduction of more diverse medical services.
Leave a comment